Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment


Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Simple Ways To Boost Online Web Traffic For Your Business This Festive Season

Previous article

‘Alice, Darling’ trailer: It’s tears and fears with this new psychological thriller

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News